Overview

Natural History of Levodopa-Induced Dyskinesia (LID)

Status:
Withdrawn
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
Levodopa is the main drug treatment for Parkinson's disease. Levodopa can cause unwanted and uncontrolled movements called dyskinesias (LID). The severity of these movements can range from subtle to extremely debilitating. These movements may or may not interfere with normal activities such as putting on a coat or brushing ones teeth. Current estimates of the occurrence rate of LID range from 12 % to 100% after one year of levodopa treatment. These estimates used reporting mechanisms such as self-report and doctor-reported. These reporting mechanisms are not reliable. We will use an objective measure of dyskinesia in the first 5 years of treatment for Parkinson's disease. The purpose of this protocol is to use an objective measure to estimate dyskinesia onset.
Details
Lead Sponsor:
Oregon Health and Science University
Collaborator:
Oregon Clinical and Translational Research Institute
Treatments:
Levodopa